NVIDIA launches Jetson Thor robotics computers for physical AI systems
On Friday, Evercore ISI issued a downgrade for Rallybio Corp (NASDAQ:RLYB), changing its rating from "Outperform" to "In Line." The adjustment came after consideration of the company’s recent study data. The market reaction has been severe, with the stock dropping 44% in the past week alone. According to InvestingPro data, RLYB’s market capitalization has contracted to just $10.53 million, though the company maintains a strong balance sheet with more cash than debt. According to Evercore ISI, the data from Rallybio’s study on FNAIT—a rare platelet disorder in fetuses and newborns—did not meet the targeted concentrations they had anticipated.
The firm’s analysts pointed out specific concerns with the confirmatory PK/PD (pharmacokinetics/pharmacodynamics) study, which is expected to commence in the second quarter of 2025, with results anticipated in the second half of the year. Despite the recent setback, analyst price targets collected by InvestingPro range from $8 to $13, suggesting significant potential upside if the company can successfully execute its development plans. InvestingPro subscribers have access to 15+ additional exclusive insights about RLYB, including detailed financial health metrics and growth projections. This study is crucial as it serves to confirm the dosage and effects of a drug that is being developed.
The downgrade reflects the analysts’ revised expectations following the recent study outcomes. The data did not align with the goals set by Rallybio for the development of their treatment, leading to a more cautious stance from Evercore ISI. The stock’s beta of -1.35 indicates it often moves counter to broader market trends, which could provide diversification benefits for portfolio managers.
Rallybio’s focus on developing treatments for severe and rare diseases means that the success of their clinical trials is critical for the company’s progress. The FNAIT study is particularly significant as it addresses a condition with limited treatment options.
The change in rating by Evercore ISI is a direct response to the latest developments in Rallybio’s clinical research. The firm will continue to monitor the company’s progress as it moves toward initiating the confirmatory PK/PD study later this year.
In other recent news, Rallybio Corporation has announced the discontinuation of its RLYB212 program after the drug failed to meet efficacy targets in a Phase 2 trial. This decision led to a downgrade by Citizens JMP analysts from Market Outperform to Market Perform, reflecting concerns over the halted program’s impact on the company’s prospects. Rallybio is now shifting focus to its other programs, including RLYB116, with a confirmatory study expected in 2025. Additionally, the company has revised its common stock offering, reducing the potential sale from $100 million to $9.55 million in a strategic amendment to its sales agreement with TD Securities.
Rallybio also faces potential delisting from the Nasdaq Stock Market due to its stock not meeting the minimum required closing bid price for 30 consecutive days. The company has been given until August 2025 to regain compliance, with options to transfer its listing to the Nasdaq Capital Market if necessary. Despite these challenges, Rallybio continues to advance its pipeline, including preclinical programs such as REV102 and RLYB332. Investors remain cautious as the company navigates these developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.